Literature DB >> 11340581

A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes.

G Cassinelli1, R Supino, P Perego, D Polizzi, C Lanzi, G Pratesi, F Zunino.   

Abstract

Loss of p53 function has been linked to increased responsiveness to taxane treatment of ovarian carcinoma in clinical studies. We recently reported that the acquisition of cisplatin resistance in an ovarian carcinoma cell line (IGROV-1) was associated with mutation of p53 and collateral sensitivity to paclitaxel. The increased sensitivity to paclitaxel of the cisplatin-resistant subline appeared to be pharmacologically relevant since it was reflected in an in vivo sensitization to taxanes. To investigate the cellular and molecular basis of this phenomenon, we performed a comparative study of cellular response to taxanes (paclitaxel and the novel analog IDN 5109) in the parental cell line, containing wild-type p53 and its cisplatin-resistant p53 mutant subline (IGROV-1/Pt1). IDN 5109 was included in this study because of its higher potency and efficacy compared with paclitaxel on both tumor systems. The pattern of cellular response of the two ovarian cell lines was different. In IGROV-1 cells, apoptosis was an early event consequent to a transient mitotic arrest. The cell death of IGROV-1/Pt1 cells was a somewhat slow and delayed event, following mitotic arrest and appearance of hyperploid cells. The increased cytotoxic effect of IDN 5109, compared with paclitaxel, was associated with more marked p34(cdc2) dephosphorylation in IGROV-1 cells and higher Bcl-2 phosphorylation in IGROV-1/Pt1 cells after 24 hr of treatment. In each cell line, these biochemical events were not correlated with parallel levels of mitotic cells. Attempts to reintroduce wild-type p53 in IGROV-1/Pt1 were unsuccessful. However, in other p53-deficient cells (osteosarcoma SAOS), taxane treatment was associated with hyperploid progression and the introduction of wild-type p53 resulted in a reduced sensivity. Although our approach does not allow definitive conclusions, these results suggest that loss of p53-dependent post-mitotic checkpoint results in a different time-course of taxane-induced cell death following DNA reduplication. These events, more evident after exposure to the potent analog IDN 5109, support the notion that the enhanced sensitivity of p53 mutant cells is closely related to the different mode of cell death. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11340581     DOI: 10.1002/1097-0215(20010601)92:5<738::aid-ijc1249>3.0.co;2-2

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  p53 expression and resistance against paclitaxel in patients with metastatic breast cancer.

Authors:  M Schmidt; A Bachhuber; A Victor; E Steiner; M Mahlke; H A Lehr; H Pilch; W Weikel; P G Knapstein
Journal:  J Cancer Res Clin Oncol       Date:  2003-04-25       Impact factor: 4.553

2.  Cyclic pifithrin-alpha sensitizes wild type p53 tumor cells to antimicrotubule agent-induced apoptosis.

Authors:  Valentina Zuco; Franco Zunino
Journal:  Neoplasia       Date:  2008-06       Impact factor: 5.715

Review 3.  Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.

Authors:  L Bracci; G Schiavoni; A Sistigu; F Belardelli
Journal:  Cell Death Differ       Date:  2013-06-21       Impact factor: 15.828

4.  Molecular mode of action and role of TP53 in the sensitivity to the novel epothilone sagopilone (ZK-EPO) in A549 non-small cell lung cancer cells.

Authors:  Sebastian Winsel; Anette Sommer; Julia Eschenbrenner; Kevin Mittelstaedt; Ulrich Klar; Stefanie Hammer; Jens Hoffmann
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

5.  Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo.

Authors:  Valentina Zuco; Michelandrea De Cesare; Raffaella Cincinelli; Raffaella Nannei; Claudio Pisano; Nadia Zaffaroni; Franco Zunino
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

6.  Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients.

Authors:  Anna Felisiak-Golabek; Alina Rembiszewska; Iwona K Rzepecka; Lukasz Szafron; Radoslaw Madry; Magdalena Murawska; Tomasz Napiorkowski; Piotr Sobiczewski; Beata Osuch; Jolanta Kupryjanczyk
Journal:  J Ovarian Res       Date:  2011-11-10       Impact factor: 4.234

Review 7.  Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies.

Authors:  P A Vasey
Journal:  Br J Cancer       Date:  2003-12       Impact factor: 7.640

8.  Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer.

Authors:  Maura Sonego; Monica Schiappacassi; Sara Lovisa; Alessandra Dall'Acqua; Marina Bagnoli; Francesca Lovat; Massimo Libra; Sara D'Andrea; Vincenzo Canzonieri; Loredana Militello; Marco Napoli; Giorgio Giorda; Barbara Pivetta; Delia Mezzanzanica; Mattia Barbareschi; Barbara Valeri; Silvana Canevari; Alfonso Colombatti; Barbara Belletti; Giannino Del Sal; Gustavo Baldassarre
Journal:  EMBO Mol Med       Date:  2013-04-22       Impact factor: 12.137

9.  TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study.

Authors:  Jolanta Kupryjanczyk; Ewa Kraszewska; Izabela Ziolkowska-Seta; Radoslaw Madry; Agnieszka Timorek; Janina Markowska; Jerzy Stelmachow; Mariusz Bidzinski
Journal:  BMC Cancer       Date:  2008-01-29       Impact factor: 4.430

10.  IDN 5390: an oral taxane candidate for protracted treatment schedules.

Authors:  G Pratesi; D Laccabue; C Lanzi; G Cassinelli; R Supino; M Zucchetti; R Frapolli; M D'Incalci; E Bombardelli; P Morazzoni; A Riva; F Zunino
Journal:  Br J Cancer       Date:  2003-03-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.